首页> 外文期刊>Journal of clinical laboratory analysis. >Urinary N-acetyl-beta-D-glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis.
【24h】

Urinary N-acetyl-beta-D-glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis.

机译:狼疮性肾炎和类风湿关节炎中的尿N-乙酰基-β-D-氨基葡萄糖苷酶(NAG)。

获取原文
获取原文并翻译 | 示例
       

摘要

Increased activity of urinary N-acetyl-beta-D-glucosaminidase (NAG) can be used as an early indicator of damage to the tubular epithelium. Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease. Nephritis is known as the most serious complication of SLE and the strongest predictor of poor outcome. In this study urinary NAG excretion was investigated in 24 SLE patients with normal renal function (serum creatinine 3.5 g/day). Serum and urinary creatinine, total urinary protein levels, and urinary NAG excretion were measured in patients with SLE and RA. In addition, serum C3 and C4 levels were determined in the SLEpatients. Renal biopsies were performed in all of the SLE patients. Glomerular lesions were classified according to WHO criteria for lupus nephritis (LN) I-V. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to assess disease activity. Urinary NAG excretion was significantly higher in the SLE groups than in the healthy controls (P<0.001). In urinary NAG excretion there was also significant difference between SLE groups and RA patients (P<0.001). However, there was no significant difference in NAG excretion between the RA and control groups (P=0.062). Urinary NAG excretion was significantly higher (P<0.05) in group B compared to group A. There were no differences in SLEDAI scores, ages, and serum creatinine levels between study groups (P=0.601, P=0.285, P=0.669, respectively). Elevated SLEDAI values and hypocomplementemia were detected more often in younger patients (P<0.010, r=-0.529 and P<0.010, r=-0.569, respectively). There was a strong positive correlation between proteinuria and urinary NAG activity (P<0.001, r=0.759). These results suggest that the determination of urinary NAG activity may be a useful supplement to the routine biochemical analysis performed on the urine in cases of SLE. J. Clin. Lab. Anal. 19:172-176, 2005. (c) 2005 Wiley-Liss, Inc.
机译:尿N-乙酰基-β-D-氨基葡萄糖苷酶(NAG)活性的提高可以用作肾小管上皮损害的早期指标。系统性红斑狼疮(SLE)是一种多系统自身免疫性风湿性疾病。肾炎是SLE最严重的并发症,也是预后不良的最强预测因子。在这项研究中,调查了24例肾功能正常(血清肌酐 3.5 g /天的患者)组成)。在SLE和RA患者中测量血清和尿肌酐,总尿蛋白水平和尿NAG排泄量。另外,在SLE患者中测定了血清C3和C4水平。所有SLE患者均进行了肾脏活检。肾小球病变根据WHO狼疮性肾炎(LN)I-V标准进行分类。系统性红斑狼疮疾病活动指数(SLEDAI)用于评估疾病活动。 SLE组尿NAG排泄明显高于健康对照组(P <0.001)。在尿液NAG排泄中,SLE组和RA患者之间也存在显着差异(P <0.001)。但是,RA组和对照组之间的NAG排泄没有显着差异(P = 0.062)。 B组的尿NAG排泄量显着高于A组(P <0.05)。研究组之间的SLEDAI评分,年龄和血清肌酐水平无差异(分别为P = 0.601,P = 0.285,P = 0.669) )。在年轻患者中更常检测到SLEDAI值升高和低补体血症(分别为P <0.010,r = -0.529和P <0.010,r = -0.569)。蛋白尿与尿液NAG活性之间存在很强的正相关(P <0.001,r = 0.759)。这些结果表明,尿液中NAG活性的测定可能是对SLE患者尿液常规生化分析的有用补充。 J.临床。实验室肛门19:172-176,2005.(c)2005 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号